Arrowhead's RNAi Triumph: First Drug Launch and $1.3B War Chest

PASADENA, CA – February 05, 2026 – Arrowhead Pharmaceuticals has decisively entered a new era, transitioning from a clinical-stage research firm to a commercial powerhouse following the landmark U.S. approval of its first drug. The company's fiscal first-quarter results for 2026 paint a picture of a biotech in rapid ascent, marked by a successful product launch, a fortified balance sheet flush with over $1.3 billion in new capital, and a burgeoning pipeline targeting some of medicine's most formidable diseases, including obesity and Alzheimer's.

The recent period included "some of the more significant achievements in our Company’s history," said Christopher Anzalone, Ph.D., President and CEO of Arrowhead. In a statement accompanying the financial results, he highlighted the regulatory approval and U.S. launch of their first product, pipeline growth, encouraging early results from obesity programs, and a meaningfully improved financial position.

A New Commercial Contender

The centerpiece of Arrowhead's transformation is REDEMPLO® (plozasiran), an RNA interference (RNAi) therapeutic approved by the U.S. Food and Drug Administration on November 18, 2025. The drug is indicated as an adjunct to diet for adults with familial chylomicronemia syndrome (FCS), a severe and rare genetic disorder that causes triglyceride levels to skyrocket, leading to a high risk of life-threatening pancreatitis. For the estimated 6,500 people in the U.S. living with FCS, effective treatments have been scarce.

Arrowhead's independent U.S. launch has shown strong initial momentum. The company reported receiving over 100 prescriptions in the early weeks, sourced from a geographically diverse base of physicians. Early patient uptake includes individuals transitioning from expanded access programs, those new to this class of therapy, and some switching from competing treatments. Notably, access has been broad, with most patients gaining reimbursement without needing to submit genetic testing results.

To facilitate access, Arrowhead introduced a patient support program, "Rely On REDEMPLO," and a "One-REDEMPLO" pricing model intended to create consistent pricing across its current and potential future indications. The global footprint for REDEMPLO is also expanding rapidly, with recent regulatory approvals secured in China, where it will be marketed by partner Sanofi, and in Canada, where Arrowhead plans to launch independently later this year.

Fueling the Future with a Billion-Dollar Boost

Supporting this commercial transition and an ambitious research agenda is a newly fortified financial position. Arrowhead executed a series of strategic financial maneuvers that injected over $1.3 billion into its coffers. This includes gross proceeds of $930 million from concurrent public offerings of common stock and convertible senior notes.

The company's partnership strategy also yielded significant returns. A global licensing deal with Novartis for a preclinical therapy targeting Parkinson's disease brought in a $200 million upfront payment, with the potential for up to $2 billion more in future milestones. Additionally, a collaboration with Sarepta Therapeutics on a treatment for type 1 myotonic dystrophy triggered a $200 million milestone payment.

This influx of capital is reflected in a dramatic financial turnaround. Arrowhead reported total revenue of $264 million for the quarter, a massive leap from just $2.5 million in the same period last year. This propelled the company to a net income of $30.8 million, a stark reversal from the $173.1 million net loss reported in the prior-year quarter. With cash and investments totaling approximately $917 million, the company has a substantial runway to fund its operations. While some industry analysts remain watchful of the high operational costs associated with R&D and a new commercial launch, the robust cash reserves provide a powerful shield against the funding pressures that often challenge biopharmaceutical companies.

Beyond Rare Disease: A Pipeline Targeting Major Ailments

While REDEMPLO's approval is a landmark achievement, Arrowhead is leveraging the validation of its proprietary Targeted RNAi Molecule (TRiM™) platform to pursue a diverse pipeline with blockbuster potential. The company is demonstrating that its gene-silencing technology can be aimed at conditions affecting millions.

Plozasiran, the active drug in REDEMPLO, has already received Breakthrough Therapy designation from the FDA for a much broader condition: severe hypertriglyceridemia (SHTG). This signals a potentially much larger market for the drug beyond the rare FCS population.

Perhaps most exciting are the early but promising results from its programs targeting obesity. In a clinical study, the investigational candidate ARO-INHBE, when combined with the popular diabetes drug tirzepatide, nearly doubled the weight loss seen with tirzepatide alone. The therapy also produced a roughly threefold improvement in the reduction of harmful visceral and liver fat. Another candidate, ARO-ALK7, also showed significant visceral fat reduction as a monotherapy.

The company is also breaking new ground in cardiovascular and neurological medicine. It recently dosed the first patients in a trial for ARO-DIMER-PA, the first-ever RNAi therapeutic designed to silence two distinct genes—PCSK9 and APOC3—simultaneously to treat atherosclerotic cardiovascular disease. Even more ambitious is ARO-MAPT, a candidate for tauopathies like Alzheimer's disease. This program represents Arrowhead's first foray into the central nervous system with a novel delivery system that, in preclinical studies, successfully crossed the blood-brain barrier after a simple subcutaneous injection, a long-sought goal in neurological drug development. These advancements signal a strategic expansion, using a validated technology platform to tackle some of the most prevalent and difficult-to-treat diseases facing society today.